The hospitals market will be the largest segment of the GLP-1 receptor agonist market segmented by end users, accounting for 57% or $79,864 million of the total in 2030
TABLE 2 [i] CBSRCT Cambridge Brain Sciences Reasoning and Concentration Tests, ImPACT Immediate Post-Concussion Assessment and Cognitive Testing, LTRT Light Tracking Reaction Test, MEL Micro Experimental Laboratory software, MTQ48 mental toughness assessment, NM not mentioned, NR not reported, PEBL Psychology Experiment Building Language, R reported, RCT randomized controlled trial, VAS visual analogue scale
PlexusDx's $298 genetic test identifies variants in other peptide pathways that influence how your body absorbs and responds to semaglutide injections
So there's added benefit of using this type of medication in someone who has obesity and has harm to their health